Phase 2Completed

A Study to Evaluate Antiviral Activity of Darunavir + Ritonavir in HIV-1 Infected Adolescents (DIONE)

A Phase II, Open-Label Trial, to Evaluate Pharmacokinetics, Safety, Tolerability and Antiviral Activity of Drv/Rtv Once Daily in Treatment-Naive HIV-1 Infected Adolescents Aged Between 12 and < 18 Years

Sponsor
Tibotec Pharmaceuticals, Ireland (Industry)
Enrollment
12 enrolled
Conditions
HIV-1 Infection
Interventions
darunavir; ritonavir; zidovudine; lamivudine; abacavir
Ages
children, adults
Registry
NCT00915655, EUCTR2008-004631-37

Full record on ClinicalTrials.gov

From the registry

The purpose of this study is to evaluate pharmacokinetics (what body does to medication), safety, tolerability, and efficacy (effectiveness) of darunavir with low-dose ritonavir (DRV/rtv) administered once daily, in combination with an investigator-selected background regimen consisting of other antiretrovirals (ARVs) ie, 2 nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs), in treatment-naive (never treated before) HIV-1 infected adolescents aged from 12 to \<18 years and weighing at least 40 kg.

Primary outcomes

  • Virological Response[Viral Load <50 Copies/mL, TLOVR]

History

  1. Last registry update

  2. Results first posted

  3. Study completion

  4. Primary completion

  5. Started

  6. Registered